Filing Flows › Johnson & Johnson (JNJ) › Q3 2026 › vs Q3 2025
Johnson & Johnson (JNJ) Q3 2026 vs Q3 2025 (year over year)
Johnson & Johnson's revenue rose $1.4B (+6%) from $24.0B in Q3 2025 to $25.4B in Q3 2026. The biggest changes: Innovative Medicine +$1.2B (+8%); MEDTECH +$212M (+3%). Gross margin 68.1% against 69.6% (-1.4 pts).
Johnson & Johnson, Q3 2026: revenue $25.4B (+6% year over year), operating margin 0.1%, net earnings $210M, operating cash flow $7.7B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 68.1% | 69.6% | -1.4 pts |
| Operating margin | 0.1% | 31.2% | -31.1 pts |
| Net margin | 0.8% | 21.5% | -20.6 pts |
| Free cash flow margin | 25.0% | 33.4% | -8.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Innovative Medicine | $16.8B | $15.6B | $1.2B | +8% |
| MEDTECH | $8.6B | $8.4B | $212M | +3% |
| Revenue | $25.4B | $24.0B | $1.4B | +6% |
| Gross profit | $17.3B | $16.7B | $612M | +4% |
| Cost of revenue | $8.1B | $7.3B | $794M | +11% |
| Operating profit | $34.0M | $7.5B | −$7.5B | -100% |
| Operating expenses | $17.3B | $9.2B | $8.1B | +88% |
| Pre-tax earnings | $34.0M | $7.5B | −$7.5B | -100% |
| Income tax benefit | $176M | −$2.3B | $2.5B | — |
| Net earnings | $210M | $5.2B | −$4.9B | -96% |
| Depreciation & amortization | $2.1B | $1.8B | $340M | +19% |
| Share-based compensation | $357M | $347M | $10.0M | +3% |
| Working capital & other | $5.0B | $1.9B | $3.1B | +166% |
| Operating cash flow | $7.7B | $9.2B | −$1.4B | -16% |
| Free cash flow (OCF − capex) | $6.4B | $8.0B | −$1.7B | -21% |
| Capital expenditures | $1.4B | $1.2B | $205M | +18% |
Questions
How much did Johnson & Johnson's revenue grow year over year in Q3 2026?
Johnson & Johnson's revenue rose $1.4B (+6%) from $24.0B in Q3 2025 to $25.4B in Q3 2026.
What drove Johnson & Johnson's revenue change in Q3 2026?
Innovative Medicine +$1.2B (+8%); MEDTECH +$212M (+3%).